LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,410 | -6.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,500 | +28.2% | 1,000 | 0.0% | 0.00% | – |
| Q4 2022 | $1,170 | -99.9% | 1,000 | 0.0% | 0.00% | – |
| Q3 2022 | $1,130,000 | -28.5% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $1,580,000 | +2.6% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,540,000 | -37.1% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $2,450,000 | -2.8% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $2,520,000 | -11.6% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $2,850,000 | +21.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $2,350,000 | +33.5% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,760,000 | +87.8% | 1,000 | 0.0% | 0.00% | – |
| Q3 2020 | $937,000 | +7.7% | 1,000 | 0.0% | 0.00% | – |
| Q2 2020 | $870,000 | +86900.0% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $1,000 | -50.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $2,000 | +100.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $1,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 5,036,720 | $14,354,000 | 4.77% |
| BROADWOOD CAPITAL INC | 34,005,379 | $96,915,000 | 4.33% |
| Prescott General Partners LLC | 1,851,851 | $5,278,000 | 0.17% |
| Raffles Associates | 43,590 | $124,000 | 0.10% |
| Laidlaw Wealth Management LLC | 123,730 | $353,000 | 0.09% |
| DCF Advisers, LLC | 74,500 | $212,000 | 0.08% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $128,000 | 0.07% |
| Strategic Wealth Investment Group, LLC | 64,232 | $183,000 | 0.06% |
| Paradigm, Strategies in Wealth Management, LLC | 19,775 | $56,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $137,000 | 0.05% |